China has ushered in new era in cancer treatment with groundbreaking drug for lung cancer developed by country’s pharmaceutical company, Akeso.

Mew drug known as Ivonescimab has gained global attention for its remarkable effectiveness, reportedly surpassing the well-known American drug Keytruda.

There was time when cancer diagnosis considered a death sentence. But thanks to relentless efforts by researchers significant progress has been made in cancer treatment. Chinese researchers claim revolutionary achievement with their new drug Ivonescimab.

Akeso stated that their drug has outperformed Keytruda in treating lung cancer. “Many global companies have tried to create an alternative to Keytruda, but all failed. We are the first to succeed,” said a representative from Akeso.

According to data from the World Conference on Lung Cancer patients who used Ivonescimab reportedly stayed healthy for an average of over 11 months, compared to just over 5 months with Keytruda.

So far, American-made Keytruda has generated around $130 billion USD in revenue marking it as major breakthrough in cancer treatment. Analysts predict that if Ivonescimab proves to be more effective than Keytruda it could significantly disrupt the global cancer treatment market.

Read more: Severe Water Crisis Grips Gaza Amid Ongoing Conflict; UNICEF Warns of Humanitarian Catastrophe

Experts believe China’s rapid advancements in medical research fueled by its robust research infrastructure, lower costs and a larger patient base. While United States currently leads in research and development, China is rapidly closing the gap.